World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
10454
World Ranking
3895
National Ranking
341

Mark R. Wills publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark R. Wills sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 160 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark R. Wills D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark R. Wills sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 54 D-Index — 22nd percentile

22% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark R. Wills is affiliated with the University of Cambridge in the United Kingdom. Their research primarily focuses on the fields of Medicine and Immunology and Microbiology, with significant contributions to several subfields including Infectious Diseases, Epidemiology, Immunology, Neurology, and Molecular Biology.

The research topics covered by Mark R. Wills include:

  • SARS-CoV-2 and COVID-19 Research
  • Cytomegalovirus and herpesvirus research
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • Immune Cell Function and Interaction
  • Herpesvirus Infections and Treatments
  • HIV Research and Treatment

Recent papers by Mark R. Wills include:

  • Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease, 2021, Immunity
  • SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies, 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial, 2020, The Lancet
  • The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People, 2020, Frontiers in Cellular and Infection Microbiology
  • Spontaneous, persistent, T cell-dependent IFN-γ release in patients who progress to Long Covid, 2024, Science Advances

Mark R. Wills frequently collaborates with several researchers including:

  • John Sinclair
  • John R. Bradley
  • Paul Lyons
  • Kenneth G. C. Smith
  • Sarah Jackson

The most common publication venues for Mark R. Wills are:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cell Reports
  • SSRN Electronic Journal
  • Frontiers in Cellular and Infection Microbiology
  • Frontiers in Immunology

Best Publications

  • The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.

    M. R. Wills;A. J. Carmichael;K. Mynard;X. Jin

  • Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2.

    Dami A Collier;Dami A Collier;Isabella A T M Ferreira;Prasanti Kotagiri;Rawlings P Datir;Rawlings P Datir

  • Ribosome Profiling Reveals Pervasive Translation Outside of Annotated Protein-Coding Genes

    Nicholas T. Ingolia;Gloria A. Brar;Noam Stern-Ginossar;Michael S. Harris;Michael S. Harris

  • Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

    Dami A. Collier;Dami A. Collier;Anna De Marco;Isabella A. T. M. Ferreira;Bo Meng

  • Functional Heterogeneity and High Frequencies of Cytomegalovirus-Specific CD8+ T Lymphocytes in Healthy Seropositive Donors

    Geraldine M. A. Gillespie;Mark R. Wills;Victor Appay;Chris O'Callaghan

  • Human cytomegalovirus immunity and immune evasion.

    Sarah E. Jackson;Gavin M. Mason;Mark R. Wills

  • Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.

    Laura Bergamaschi;Federica Mescia;Lorinda Turner;Aimee L. Hanson

  • Identification of Naive or Antigen-Experienced Human CD8 + T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8 + T Cell Response

    Mark R. Wills;Georgina Okecha;Michael P. Weekes;Maher K. Gandhi

  • The Memory Cytotoxic T-Lymphocyte (CTL) Response to Human Cytomegalovirus Infection Contains Individual Peptide-Specific CTL Clones That Have Undergone Extensive Expansion In Vivo

    Michael P. Weekes;Mark R. Wills;Kim Mynard;Andrew J. Carmichael

  • HUMAN VIRUS-SPECIFIC CD8+ CTL CLONES REVERT FROM CD45ROHIGH TO CD45RAHIGH IN VIVO : CD45RAHIGHCD8+ T CELLS COMPRISE BOTH NAIVE AND MEMORY CELLS

    M. R. Wills;A. J. Carmichael;M. P. Weekes;K. Mynard

  • Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.

    Mair Thomas;Jessica M Boname;Sarah Field;Sergey Nejentsev

  • CMV and Immunosenescence: from basics to clinics

    Rafael Solana;Raquel Tarazona;Allison E Aiello;Arne N Akbar

  • Human Cytomegalovirus Encodes an MHC Class I-Like Molecule (UL142) That Functions to Inhibit NK Cell Lysis

    Mark R. Wills;Omodele Ashiru;Matthew B. Reeves;Georgina Okecha

  • Human CD28−CD8+ T Cells Contain Greatly Expanded Functional Virus-Specific Memory CTL Clones

    M. P. Weekes;A. J. Carmichael;M. R. Wills;K. Mynard

  • Rapid CD8+ T Cell Repertoire Focusing and Selection of High-Affinity Clones into Memory Following Primary Infection with a Persistent Human Virus: Human Cytomegalovirus

    Elizabeth K. Day;Andrew J. Carmichael;Ineke J. M. ten Berge;Edward C. P. Waller

  • Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2

    Dami Collier;Anna De Marco;Isabella Ferreira;Bo Meng

  • Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population.

    M. P. Weekes;M. R. Wills;K. Mynard;R. Hicks

  • Latency and reactivation of human cytomegalovirus

    J.G.P Sissons;M Bain;M.R Wills

  • NKG2D Ligand MICA Is Retained in the cis-Golgi Apparatus by Human Cytomegalovirus Protein UL142

    Omodele Ashiru;Neil J. Bennett;Louise H. Boyle;Mair Thomas

  • The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?

    Mark R Wills;Emma Poole;Betty Lau;Ben Krishna

  • Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension

    Mark L. Ormiston;Chiwen Chang;Lu L. Long;Elaine Soon

  • Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial

    S Fidler;W Stöhr;M Pace;L Dorrell

Frequent Co-Authors

John Sinclair
John Sinclair University of Cambridge
Andrew M. L. Lever
Andrew M. L. Lever University of Cambridge
Kenneth G. C. Smith
Kenneth G. C. Smith Walter and Eliza Hall Institute of Medical Research
Rainer Doffinger
Rainer Doffinger University of Cambridge
Paul J. Lehner
Paul J. Lehner University of Cambridge
Paul A. Lyons
Paul A. Lyons University of Cambridge
Barbara J. Graves
Barbara J. Graves University of Utah
John Trowsdale
John Trowsdale University of Cambridge
Gordon Dougan
Gordon Dougan University of Cambridge
Maher K. Gandhi
Maher K. Gandhi University of Queensland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology opens doors to various healthcare professions, many of which benefit from accelerated and flexible online programs. For those interested in advancing to clinical roles swiftly, accelerated FNP programs offer a fast track to becoming a Family Nurse Practitioner, blending immunology knowledge with patient care expertise.

Individuals without a nursing background can explore 12-month accelerated nursing programs online for non nurses, enabling a quick transition into nursing roles that often intersect with immunology in clinical environments.

For those starting their nursing journey, identifying accessible entry points is crucial. The easiest ABSN program to get into can provide an efficient gateway to a Bachelor of Science in Nursing, facilitating deeper engagement with immunological principles in healthcare settings.

Additionally, easiest LPN programs to get into offer practical nursing education with shorter timelines, making them ideal for those seeking quick entry to roles that support immunology-related patient care.

Best Scientists Citing Mark R. Wills

Trending Scientists

Recently Published Articles